Chronic frequent headache in the general population: comorbidity and quality of life
Wiendels, N.J.; Haestregt, A. van; Knuistingh Neven, A.; Spinhoven, P.; Zitman, F.G.; Assendelft, W.J.J.; Ferrari, M.D.

Citation

Version: Not Applicable (or Unknown)
License: Leiden University Non-exclusive license
Downloaded from: https://hdl.handle.net/1887/13184

Note: To cite this publication please use the final published version (if applicable).
Chronic frequent headache in the general population: comorbidity and quality of life

NJ Wiendels1,2, A van Haestregt1, A Knuistingh Neven2, P Spinhoven3, FG Zitman4, WJJ Assendelft2 & MD Ferrari1
Departments of 1Neurology, 2General Practice and Nursing Home Medicine, 3Psychology and 4Psychiatry, Leiden University Medical Centre, Leiden, the Netherlands

We studied the nature and extent of comorbidity of chronic frequent headache (CFH) in the general population and the influence of CFH and comorbidity on quality of life. Subjects with CFH (headache on >14 days/month) were identified in a general health survey. We sent a second questionnaire including questions on comorbidity and quality of life to subjects with CFH and subjects with infrequent headache (IH) (1–4 days/month). We recoded comorbidity by using the Cumulative Illness Rating Scale (CIRS) and measured quality of life with the RAND-36, a Dutch version of Short Form-36. CFH subjects (n = 176) had higher comorbidity scores than the IH subjects (n = 141). Mean CIRS scores were 2.94 for CFH and 1.55 for IH [mean difference 1.40, 95% confidence interval (CI) 0.91, 1.89]. The mean number of categories selected was 1.92 in CFH and 1.10 in IH (mean difference 0.82, 95% CI 0.54, 1.11). Fifty percent of CFH subjects had a comorbidity severity level of at least 2, indicating disorders requiring daily medication, compared with 28% of IH subjects (mean difference 22%, 95% CI 12, 33). CFH subjects had more musculoskeletal, gastrointestinal, psychiatric and endocrine/breast pathology than IH subjects. Quality of life in CFH subjects was lower than that of IH subjects in all domains of the RAND-36. Both headache frequency and CIRS score had a negative influence on all domains. We conclude that patients with CFH have more comorbid disorders than patients with infrequent headaches. Many CFH patients have a comorbid chronic condition requiring daily medication. Both high headache frequency and comorbidity contribute to the low quality of life in these patients.

Introduction
Epidemiological studies on comorbidity of headache disorders have focused primarily on psychiatric disorders. Migraine has been repeatedly found to be associated with major depression and anxiety disorders (1–4). Breslau et al. found a bi-directional relationship between migraine and major depression; a history of major depression is a risk factor for migraine and migraine increases the risk for major depression (3). They suggested that shared underlying factors explain the co-occurrence of the two disorders, rather than major depression being a psychological response to recurrent severe headaches.

Chronic frequent headache (CFH), also known as chronic daily headache, is defined as headache on
In headache clinics, the majority of patients with CFH have a comorbid psychiatric disorder (7–9). The most commonly reported disorders are major depression and generalized anxiety disorder, followed by panic disorder and phobias. High headache frequency and chronic substance use are associated with higher scores on anxiety and depression scales (10, 11). In a general population sample, aged >64 years, a high score on a depression scale was associated with CFH and subjects with CFH were at increased risk of major depression at follow-up (12).

Few studies have explored comorbidity of headache with somatic disorders. Associations of migraine with epilepsy, stroke, asthma and chronic musculoskeletal pain have been reported (13–15). CFH has been associated with allergies, asthma, hypothyroidism, hypertension, sleep disorders and fibromyalgia (16, 17). These studies were conducted in headache clinics, which might have led to an overestimation of associations, because referred patients may represent a selected, difficult to treat population. To avoid this bias, population-based studies are preferred.

The overall comorbidity of CFH in the general population has not been studied systematically. Co-occurrence of diseases can complicate diagnosis, due to symptomatic overlap of the two conditions, and can have important implications for treatment. Moreover, comorbidity can have a negative influence on quality of life. Quality of life is reduced in subjects with CFH and is greatly influenced by anxiety and depressive disorders (18–20). We studied the nature and extent of comorbidity in CFH patients in the general population and examined the influence of CFH and comorbidity on quality of life.

Methods

We conducted a general health survey amongst all persons, aged 25–55 years, registered at 16 general practices in the province of South-Holland in the Netherlands in 2003. This sample represents the general population because in the Netherlands all individuals are registered at a general practice. The study design and methodology have been described in detail previously (21). In short, 76% completed the general health survey. We identified subjects with CFH, defined as headache on >14 days per month during the past 3 months, and sent them a second, more detailed questionnaire containing questions on comorbidity and quality of life. Forty percent completed the questionnaire. Non-responders showed no relevant demographic differences from the responders. A random sample of subjects with infrequent headache (IH), defined as headache on 1–4 days per month, served as the control group. The majority (62%) of subjects with CFH overused acute headache medication. This study was conducted before the publication of the revised International Headache Society criteria for medication overuse headache. We defined overuse as: the use of analgesics on ≥3 days/week, the use of triptans on ≥2 days/week, the use of ergots on ≥1 day/week or the use of narcotics on ≥10 days/month. Overuse consisted mainly of analgesics, only three (2%) overused triptans, one ergotamine and seven (4%) narcotics.

Comorbidity was assessed by the following open questions: (i) ‘Do you have a disorder for which you have to consult your physician regularly?’; (ii) ‘Do you have other disorders for which regular consultation is not necessary at the moment?’; (iii) ‘Have you been admitted to hospital in the past? If yes, please specify’; (iv) ‘Which medication (including painkillers) do you use?’ We recoded answers by using the Cumulative Illness Rating Scale (CIRS) (22). The CIRS is a reliable and validated comorbidity questionnaire and shows close resemblance to common clinical practice: it is structured according to 14 body systems and uses a clear severity ranking that is clinically sound (23–27). The worst problem in a specific organ system is rated on a scale from 0 to 4 (0, none; 1, current mild problem or significant problem in the past; 2, moderate disability/requires daily medication; 3, severe/constant disability, uncontrollable chronic problem; and 4, extremely severe/immediate treatment required/end organ failure/severe impairment in function). Five summary scores can be calculated [total CIRS score, total number of categories endorsed, severity index (total score/total number of categories) and number of level 3 and 4 severity] (22). The total CIRS score was our main outcome measure. Headache, our index disease, was not rated as a comorbid disorder. Whenever the manual of the CIRS was not clear about how to rate a certain symptom or disease, we rated the symptom by consensus and used a data file to record our decisions. We modified the psychiatric illness rating as follows: current usage of daily antidepressants or anxiolytics without sleeping problems was rated as severity 2, and psychiatric illness with daily use of two medications as severity 3. Frequent sleeping problems were listed under neurological comorbidity, with occasional use of hypnotics as severity 1.
and daily use of hypnotics as 2. Use of benzodiazepines without a specified indication was rated according to their registered indication (e.g. diazepam as anxiolytic).

Quality of life was measured by the RAND-36, a Dutch version of the RAND-36-Item Short Form Health Survey, a commonly used generic quality of life questionnaire (28). The RAND-36 has been shown to have excellent reliability and validity when employed with diverse patient populations in the Netherlands (29). It consists of eight domains of well-being and functioning, including Physical Functioning (PF), Social Functioning (SF), Physical Role Functioning (PRF), Emotional Role Functioning (ERF), Mental Health (MH), Vitality (V), Bodily Pain (BP) and General Health (GH), and an additional item, Health Transition (HT). The scales range from 0 to 100, with higher scores indicating better quality of life.

Data analysis was performed using SPSS 11.0 (SPSS Inc., Chicago, IL, USA). Differences are presented with 95% confidence intervals (95% CI). Differences in comorbidity categories and quality of life domains between CFH subjects and IH subjects were tested for significance. Due to multiple comparisons we applied a Bonferroni adjustment yielding an \( \alpha \) level of 0.003 for the CIRS categories and 0.006 for the RAND-36 domains (30). The relationship between RAND-36 scores and CIRS scores was investigated using Spearman’s rank order correlation. Values between 0.10 and 0.29 were considered to indicate a weak correlation, between 0.30 and 0.49 a medium strong correlation and between 0.50 and 1.0 a strong correlation. Hierarchical multiple regression was used to examine the relationship between each RAND-36 domain and headache frequency (case status) while controlling for educational level and CIRS score.

**Results**

Table 1 shows the demographic characteristics of both headache groups. The CFH group had more subjects with a lower educational level. The presence of comorbidity is summarized in Table 2. One CFH subject did not complete the comorbidity section of the questionnaire and was excluded from analysis. In both headache groups, the majority currently had or had had in the past at least one comorbid problem. Of 149 CFH subjects with any comorbidity, 60% had a severity level of at least 2, indicating disorders requiring daily medication (e.g. hypertension).

In both groups the most prevalent comorbid disorders were in the gastrointestinal and musculoskeletal/skin categories. In the CFH group 21 of 24 subjects (88%) with upper gastrointestinal problems reported heartburn, 19 used antacids or acid suppressants, six of them in combination with non-steroidal anti-inflammatory drugs (NSAIDs). In the IH group four of seven subjects (57%) used acid suppressants. Lower gastrointestinal problems were mainly appendectomies in the past—16 (9%) CFH, five (4%) IH; or other operations—seven (4%) CFH, seven (5%) IH. In the musculoskeletal/skin category, joint operations in the past—19 (11%) CFH, 14 (10%) IH, and arthritis; 10 (6%) CFH, five (4%) IH were the most commonly reported disorders, followed by back pain—nine (5%) CFH, six (4%) IH; and neck pain/whiplash—seven (4%) CFH, 0 IH. Six CFH subjects (3%) reported fibromyalgia, none in the IH group. Dermatological disorders were reported only once in the CFH group and four times in the IH group.

CFH subjects had more endocrine/breast, psychiatric and neurological pathology than the IH subjects. The endocrine/breast group consisted of a sum of several disorders: thyroid pathology, diabetes and breast cancer. In the psychiatry group, the following comorbid problems contributed most to the ratings: depressive mood or current use of antidepressants—11 (6%) CFH, two (1%) IH; anxiety disorder or current use of anxiolytics—13 (7%) CFH, three (2%) IH; current use of both antidepressants and anxiolytics—five (3%) CFH, one (0%) IH. The differences in neurological ratings were mainly due to sleeping problems or current use of hypnotics—22 (13%) CFH, nine (6%) IH.

<table>
<thead>
<tr>
<th></th>
<th>CFH</th>
<th>IH</th>
<th>Difference, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, years (SD)</td>
<td>43 (8.4)</td>
<td>42 (8.0)</td>
<td>0.5 (−1.5, 2.4)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>125 (72)</td>
<td>97 (70)</td>
<td>2% (−8, 12)</td>
</tr>
<tr>
<td>Low educational level, n (%)</td>
<td>62 (35)</td>
<td>16 (11)</td>
<td>24% (15, 33)</td>
</tr>
</tbody>
</table>

CFH, Chronic frequent headache (>14 days/month); IH, infrequent headache (1–4 days/month).

© Blackwell Publishing Ltd Cephalalgia, 2006, 26, 1443–1450
Other reported disorders were epilepsy—six (3%) CFH; hernia—five (3%) CFH, three (2%) IH; and miscellaneous disorders—eight (5%) CFH, six (4%) IH. In both psychiatric and endocrine/breast categories the difference between CFH subjects and IH subjects was significant at the adjusted level of 0.003, but not in the gastrointestinal, musculoskeletal and neurological categories.

CFH subjects had higher total CIRS scores than IH subjects (Table 3). Median number of categories endorsed was two in the CFH group vs. one in the IH group. CFH was associated with a CIRS comorbidity level of at least 2 with a crude odds ratio of 2.6 (95% CI 1.6, 4.2), and adjusted for educational level 2.2 (95% CI 1.3, 3.5). In the CFH group over-users had higher total CIRS scores than non-overusers (Table 4), but severity was not significantly higher.

Quality of life of CFH subjects was lower in all domains of the RAND-36 compared with the IH subjects (Fig. 1). Scores for Health Transition were 45.2 in the CFH group and 54.6 in the IH group, mean difference \(-9.4\) (95% CI \(-14.3, -4.5\)). Small differences in quality of life between subjects who overused acute headache medication and those who did not were not statistically significant (Fig. 2). All domains of the RAND-36 were negatively correlated with CIRS score (Table 5). Hierarchical multiple regression showed that after controlling for educational level and CIRS score,
CFH case status remained an independent predictor of all RAND-36 domains. Case status explained 5% (Emotional Role Functioning) to 25% (Bodily Pain) of the variance.

Discussion

To the best of our knowledge, the overall comorbidity of CFH has not previously been studied systematically in a population-based sample. Subjects with CFH reported more somatic and psychiatric comorbidity than subjects with infrequent headaches. Overusers reported more comorbidity than non-overusers. Fifty percent of the CFH subjects had a comorbid problem causing at least moderate disability or requiring daily medication (severity level ≥2).

The CIRS is meant to give a global estimate of medical burden taking into account both the presence and the severity of disorders. Its accuracy depends on the ability of subjects to report diseases. Self-reports have proven to be reasonably accurate for estimations of prevalent health conditions (24, 31). The number of comorbid problems in our study was lower than reported in other studies using the CIRS (24, 25). This is probably due to the lower mean age of our participants and the population-based setting. We think our results are a reliable estimate of the overall prevalence of comorbidity in headache patients in the general population.

Table 4 CIRS scores in overusers compared with non overusers

<table>
<thead>
<tr>
<th></th>
<th>Overuse, n = 109</th>
<th>No overuse, n = 67</th>
<th>Difference, (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total CIRS score</td>
<td>3.34 (2.62)</td>
<td>2.28 (2.21)</td>
<td>1.06 (0.30, 1.81)</td>
</tr>
<tr>
<td>Number of categories endorsed</td>
<td>2.11 (1.43)</td>
<td>1.60 (1.35)</td>
<td>0.51 (0.08, 0.94)</td>
</tr>
<tr>
<td>Severity index</td>
<td>1.51 (0.50)</td>
<td>1.38 (0.44)</td>
<td>0.13 (−0.03, 0.29)</td>
</tr>
<tr>
<td>Comorbidity severity level ≥2, n (%)</td>
<td>61 (56)</td>
<td>27 (40)</td>
<td>16% (0, 31)</td>
</tr>
<tr>
<td>Comorbidity severity level 3, n (%)</td>
<td>21 (24)</td>
<td>6 (9)</td>
<td>15% (−1, 14)</td>
</tr>
<tr>
<td>Comorbidity severity level 4, n (%)</td>
<td>2 (2)</td>
<td>0 (0)</td>
<td>2% (−1, 5)</td>
</tr>
</tbody>
</table>

Values are means (SD), unless stated otherwise. CIRS, Cumulative Illness Rating Scale.

Figure 1 Mean RAND-36 scores (28) in the chronic frequent headache (CFH, □) (n = 173) and infrequent headache (IH, ■) (n = 141) groups. CFH differs significantly from IH in all domains (P < 0.001). PF, Physical functioning; SF, social functioning; PRF, physical role functioning; ERF, emotional role functioning; MH, mental health; V, vitality; BP, bodily pain; GH, general health.

Figure 2 Mean RAND-36 scores (28) in the chronic frequent headache (CFH) group with (□, n = 107) and without (■, n = 66) overuse of acute headache medication. Differences are not statistically significant. PF, Physical functioning; SF, social functioning; PRF, physical role functioning; ERF, emotional role functioning; MH, mental health; V, vitality; BP, bodily pain; GH, general health.

CFH case status remained an independent predictor of all RAND-36 domains. Case status explained 5% (Emotional Role Functioning) to 25% (Bodily Pain) of the variance.
two or more co-occurring chronic or recurrent diseases within one person in general practice was 29.7%.

Musculoskeletal problems were frequently reported. Although not significant after Bonferroni correction, chronic pain conditions tended to be present more frequently in CFH than in IH subjects. Headache has been associated with musculoskeletal pain in the general population before; migraine was associated with chronic back pain, and low back pain in adolescents with headache (15, 33). In a headache clinic, Peres et al. diagnosed fibromyalgia in 36% of chronic migraine patients (16). Although we did not find such a high prevalence, six CFH subjects reported fibromyalgia vs. none in the IH group. Central sensitization, a pathological change in central pain processing, could play a role in the co-occurrence of these chronic pain conditions (34).

Many CFH subjects reported gastrointestinal problems. Heartburn, a symptom of gastroesophageal reflux disease, was the most frequently reported upper gastrointestinal disorder. It is a common health problem and has considerable impact on quality of life (35). Heartburn in the CFH group could not be attributed entirely to NSAID gastropathy since only 25% of CFH subjects with heartburn used NSAIDs. The higher gastrointestinal comorbidity in CFH subjects compared with IH subjects might reflect a higher anxiety and perceived stress level in CFH subjects (36).

The prevalence of psychiatric disorders in CFH in the general population has never been studied. In the elderly in Taiwan, CFH was associated with high scores on a depression scale (12). Studies in headache clinics have shown that CFH was associated with depression and anxiety disorders (7–9). It was not surprising, therefore, to find more psychiatric pathology in the CFH group than in the IH group. However, the percentage of subjects with psychiatric comorbidity in the CFH group was lower than expected. We previously found that the majority of our CFH subjects screen positive for psychopathology on the General Health Questionnaire (21). The prevalence of self-reported psychiatric comorbidity may have been underestimated due to hesitation to report psychiatric problems or simply because they may not yet have been diagnosed. The true prevalence of psychiatric disorders can be assessed only by an interview based on Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria.

Endocrine/breast disorders were present more frequently in the CFH group than in the IH group. The endocrine/breast category consisted of various disorders, the numbers being too small for meaningful subanalyses.

The RAND-36 scores in the IH group were similar to normal values. Quality of life is clearly impaired in the CFH group. Physical Role Functioning and Vitality scored the lowest. The difference between CFH and IH was most marked for Physical Role Functioning and Bodily Pain. The Physical Role Functioning domain measures whether one cannot fulfil one’s role/work because of a physical problem. Considering the high prevalence of CFH, the low score in this particular domain implies that CFH not only affects a subject’s personal life but also has a major impact on society. Our results are comparable to those of other studies. In Spain, two studies found similar decreases of quality of life measured with the SF-36 in subjects with CFH in the general population. Both Colas et al. and Guitera et al. found Physical Role Functioning, Bodily Pain and Vitality to be the most affected domains (19, 20). Guitera et al. also found that subjects with analgesic overuse scored lower than the non-overusers in all domains, especially Physical Functioning and Bodily Pain. In our study the small differences between overusers and non-overusers were not statistically significant, indicating that overuse causes only minor to no extra impairment. Both headache frequency and comorbidity had a negative influence on quality of life. Logically, headache frequency showed a strong influence on Bodily Pain and CIRS score on General Health.

A limitation of this study is that comorbidity rating is based on open general questions on comorbid disorders. If questions on specific symptoms, such as joint or back pain, had been included,
we assume that certain body systems (e.g. musculoskeletal) might have scored higher. Our data also lacked information on various objective parameters such as body mass index and levels of serum cholesterol and haemoglobin, data that would surely have increased endocrine, vascular and haematopoietic comorbidity scores. However, we did not aim to find specific disease prevalence rates or associations, but rather to form an impression of the extent of comorbidity experienced by and thus most likely proving burdensome to the headache patient. Causal relationships cannot be proved by this cross-sectional study.

In conclusion, CFH patients in the general population have more somatic and psychiatric comorbidity than patients with infrequent headaches. Many CFH patients have a comorbid chronic condition requiring daily medication. Both high headache frequency and comorbidity contribute to the low quality of life in these patients. The relatively high prevalence of CFH, the high comorbidity rate and the low quality of life indicate that CFH is a major health problem.

Competing interests

None declared.

Acknowledgements

This study was supported by a grant of the Netherlands Organization for Scientific Research (NWO 940-31-049) and by the ‘Doelmatigheidsfonds van het LUMC’ (LUMC fund to increase efficiency in healthcare). We thank the following GPs for their participation: K. F. van de Bent, A. Boels, J. J. F. M. Brinkmann, T. Buiter-van der Kooi, H. A. Dirkse, L. van Duijn, F. M. M. van Exter, F. G. W. M. Haase, H. van Klei, J. Klein Hanefeld, W. Libeton, C. H. Luitrink, E. H. J. Smids, M. H. C. van der Velden, R. M. Vermeer, R. Voskuil, P. G. Willemse and B. W. de Zeeuw.

References